Genome-wide identification and analysis of prognostic features in human cancers
Genome-wide identification and analysis of prognostic features in human cancers
复制标题
DOI：
--
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
癌症的临床决策依赖于精确评估患者风险。为了提高我们识别最具侵袭性的恶性肿瘤的能力，我们使用来自10，884名患者的基因表达，拷贝数，甲基化和突变数据构建了全基因组生存模型。我们艾德了超过100，000种重要的预后生物标志物，并证明这些基因组特征可以在临床模糊的情况下预测患者的结局。虽然不利的生物标志物通常被认为代表癌症驱动基因和有前途的治疗靶点，但我们表明，与较短生存时间相关的癌症特征并不富集癌基因或成功的药物靶点。相反，最强的不良生物标志物代表广泛表达的细胞周期和管家基因，相应地，几乎所有针对这些特征的治疗都在临床试验中失败。总之，我们的分析为预后生物标志物分析建立了丰富的资源，并阐明了患者生存数据在临床前癌症研究和治疗开发中的应用。
SUMMARY Clinical decisions in cancer rely on precisely assessing patient risk. To improve our ability to identify the most aggressive malignancies, we constructed genome-wide survival models using gene expression, copy number, methylation, and mutation data from 10,884 patients. We identified more than 100,000 significant prognostic biomarkers and demonstrate that these genomic features can predict patient outcomes in clinically ambiguous situations. While adverse biomarkers are commonly believed to represent cancer driver genes and promising therapeutic targets, we show that cancer features associated with shorter survival times are not enriched for either oncogenes or for successful drug targets. Instead, the strongest adverse biomarkers represent widely expressed cell-cycle and housekeeping genes, and, correspondingly, nearly all therapies directed against these features have failed in clinical trials. In total, our analysis establishes a rich resource for prognostic biomarker analysis and clarifies the use of patient survival data in preclinical cancer research and therapeutic development.